VIARTIS
|
||||||
PARKINSON'S DISEASE NEWS |
||||||
|
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].
28th January 2018 - New research LONG TERM EFFECTS OF RASAGILINE ON PARKINSON'S DISEASE Rasagiline is a MAO inhibitor, sold as Azilect, which is used for the treatment of Parkinson's Disease. For more information go to Azilect In the long term there has been found to be no advantage in starting the use of rasagiline early rather than delaying its use. After three years the Parkinson's Disease symptoms scores did not differ between those who started early and those who delayed its use. In both groups there was a worsening of their symptoms overall. Additionally, 43% of patients had onset of unsteady gait and balance impairment, 35% had fallen, 26% had freezing of gait, and 33% had cognitive decline. Reference : Movement Disorders [2016] 31 (10) : 1489-1496 -274 (O.Rascol, R.A.Hauser, F.Stocchi, C.J.Fitzer-Attas, Y.Sidi, V.Abler, C.W.Olanow) Complete abstract For more news go to Parkinson's Disease News
E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News, please merely e-mail [email protected] with the message "subscribe". No form of identity is required. E-mail addresses are not used for any other purpose.
|
|
||||
©2006-2018 Viartis | ||||||
2018-01-28 17:44:08 | ||||||
[email protected] |